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ABSTRACT
Purpose Insulin lispro is a rapid-acting insulin analogue produced
by recombinant DNA technology. As a biosynthetic drug, the
protein undergoes strict monitoring aiming for detection and char-
acterization of impurities. The goal of this study was to isolate and
identify a derivative of insulin lispro formed during biosynthesis.
Methods For this purpose, ion exchange chromatography in
combination with endoproteinase Glu-C digestion, MALDI-TOF/
TOF mass spectrometry and Edman sequencing were employed.
Results Ion exchange chromatography analysis of related proteins
in development batches of recombinant insulin lispro revealed the
existence of unknown derivative in excess of the assumed limit. Its
molecular mass was 42 Da higher than the theoretical mass of
Lys(B31) insulin lispro—one of the expected process-related inter-
mediates. Endoproteinase Glu-C cleavage enabled indication of the
modified peptide. Tandem mass spectrometry (MS/MS) allowed to
explore the location and type of the modification. The 42 amu shift
was present in the mass of y-type ions, while b-type ions were in
agreement with theoretical values. It suggested that themodification
is present on B31 lysine. Further inquiry revealed the presence of
two diagnostic ions for lysine acetylation at m/z 143.1 and 126.1. In
addition, the peptide was isolated and sequenced by Edman deg-
radation. Standards of phenylthiohydantoin derivatives of
N-ε-acetyl-L-lysine andN-ε-trimethyl-L-lysine, not available com-
mercially, were synthesized in the laboratory. The retention time of
the modified residue confirmed its identity as N-ε-acetyl-L-lysine.
Conclusions The derivative of insulin lispro formed during bio-
synthesis of the drug was identified to be N-ε-acetyl-L-lysine
(B31) insulin lispro.
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In 1980s recombinant human insulin has been implemented
as a base treatment for patients suffering from diabetes (1).
However, when administered, the drug did not mimic physi-
ological, 24-h long profile of endogenous hormone release by
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beta-cells. Therefore, in recent years, analogues of human
insulin have been engineered to improve insulin therapy
through modulation of onset and duration of action after in-
jection. Insulin lispro is a rapid-acting insulin analogue de-
signed by inversion of two penultimate amino acids: proline
(B28) and lysine (B29) on the C-terminal end of the B-chain of
human insulin. The subtle change in the amino acid sequence
does not alter receptor binding, whereas it considerably di-
minishes the insulin’s natural propensity to self-associate to
dimers and higher order oligomers (2). Larger amounts of
active monomeric insulin available for postprandial injections
enable significantly faster glucose level reduction. As a result,
the insulin analogue shortens noticeably the time interval be-
tween the injection and a meal, offering a greater flexibility
with meal times (3).
The analogue is produced by recombinant DNA technol-
ogy in E. coli as a fusion protein which is further converted to
the functional hormone by selected enzymes. However, inher-
ent feature of all recombinant proteins is the presence of post-
translational modifications (PTMs) related to their production
system and storage (4–6). All PTMs present in a protein drug
product may potentially affect its safety and efficacy and
should be evaluated in terms of toxicity, immunogenicity
and biological activity. In living cells PTMs result in structural
and functional heterogeneity and thus can affect numer-
ous biological processes e.g. DNA replication and repair,
cellular signalling, cell growth, metabolism, development
and apoptosis (7–9). In broader perspective, understand-
ing of biological implications of PTMs on human health
is of significant value as it is still unclear if PTMs are
the cause or the consequence of certain diseases (10).
One such PTM is lysine acetylation which is gaining
increasing attention. The recent reports concerning many
thousands of acetylated proteins in both eukaryotes and pro-
karyotes suggest that lysine acetylation is involved in reg-
ulation of diverse substantial cellular processes such as
chromatin remodeling, protein synthesis, nuclear trans-
port, cell cycle and the coordination of different metabolic
pathways (11–14).
It was previously acknowledged that lysine acetylation
was regulated by enzymes such as lysine acetyltransferases
(KATs) and deacetylases (KDACs) (15). However, B. N.
Violand et al. suggested that acetylation of lysines may
occur by chemical mechanism with acetyl-CoA or another
metabolic intermediate providing the source of the acetyl
group (16). Indeed, recent studies have shown that lysine
acetylation can also proceed non-enzymatically using
acetyl-CoA (17) and acetyl phosphate (AcP) as the acetyl
donor (18). Interestingly, an analogous AcP-dependent
non-enzymatic reaction was observed earlier for phosphor-
ylation (19,20). AcP is a small-molecule metabolite in the
phosphotransacetylase (Pta)—acetate kinase (AckA) path-
way, one of the basic metabolic networks in E. coli
(19,21). In light of the recent explosion of basic research
on lysine acetylation (22–24), it seems important to recall
previous studies on acetylation of recombinant therapeutic
proteins produced in E. coli: neurotropin-3 (25), somatotro-
pin (16), interleukin-10 (26), interleukin-2 (27), chemokine
RANTES (regulated on activation, normal T cell
expressed and secreted) (17), interferon alfa (28) and gam-
ma (29), stathmin-like subdomains (30), human basic fibro-
blast growth factor mutein (31) and prochymosin (32).
These results support current attempts to understand the
mechanism of acetylation and its implications on cell life.
Moreover, new discoveries should be expected in this filed
since E. coli is still one of the most widely used expression
hosts in the biopharmaceutical industry. Nearly 30% of
currently approved recombinant therapeutic proteins are
produced in this system (33). In concern for patients, the
drug approval by regulatory authorities is dependent on
still growing demands related to its efficacy, quality and
safety (34). Impurities and derivatives of therapeutic pro-
teins should be removed in a purification step or, if pres-
ent in acceptable quantities, characterized to the greatest
possible extent.
The purpose of this work was to isolate and identify
an acetylated derivative formed during biosynthesis of
insulin lispro. The main difficulty in characterization
of the derivative was its limited availability. Moreover,
a mass coincidence between acetylated and tri-methylated
protein derivatives (see Fig. 1) was a challenge for mass spec-
trometry analysis.
We applied ion exchange chromatography to isolate the
derivative from insulin lispro substance. The derivative was
further characterized by combination of enzymatic digestion,
mass spectrometry and Edman sequencing. The results con-
firmed interchangeably that the protein isolated from a pro-
duction batch is an acetylated derivative of recombinant lispro
insulin.
Fig. 1 Structures of acetylated and trimethylated lysine residues.
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MATERIALS AND METHODS
Source of Insulin Lispro
Insulin lispro was produced by recombinant DNA tech-
nology essentially as described previously (35). Shortly,
insulin lispro precursor was expressed in E. coli in the
form of insoluble inclusion bodies. After separation from
cell debris, the precursor was transformed into insulin
lispro by enzymatic digestion with trypsin and carboxy-
peptidase B. Finally, insulin was purified by chromatog-
raphy, dialysis and crystallization.
Isolation of the Insulin Lispro Acetylated Derivative
The derivative was isolated from a development batch of in-
sulin lispro substance by repetitive ion exchange chromatog-
raphy (IEC) using ICS-5000 system with a PDA detector
(Dionex, Sunnyvale, USA). 0.1 mg of the insulin lispro con-
taining 0.8% of the derivative was injected on a DNA Pac PA-
100, 250×4.0 column (Dionex, Sunnyvale, USA). The sepa-
ration was carried out at 35°C with a linear gradient elution
from 0% to 25% eluent B in 30 min at the flow rate 0.5 ml/
min. Eluent A was 8 mM phosphate buffer, 67% ethanol
pH 7.6 and eluent B was 0.3 M NaCl, 8 mM phosphate
buffer, 67% ethanol pH 7.6. The peak of the derivative (rel-
ative retention time 0.8; see Fig. 3) was collected. This proce-
dure was repeated several times to obtain sufficient amount of
the derivative. All fractions of the derivative were pooled and
evaporated to dryness using Concentrator Plus vacuum cen-
trifuge (Eppendorf, Hamburg, Germany) and kept at −20°C
until use.
Peptide Mapping and Isolation of Peptide B22-B31
The derivative was dissolved in 0.5 ml of 0.1MHEPES buffer
pH 7.5 and mixed with 10 μl of 10 μg/ml endoproteinase
Glu-C (Protease S. aureus V8; Thermo Scientific, Rockford,
USA). The mixture was incubated for 4 h at 37°C. Then
the HPLC system (Alliance 2695, Waters, Milford, USA) with
UV detector (2489, Waters, Milford, USA), equipped with a
Zorbax SB-C18 1.8, 4.6×50 mm column (Agilent, Palo
Alto, USA), was employed to separate and isolate the
peptides. The separation was carried out at 40°C with a
linear gradient elution from 10% to 50% eluent B in
20 min at a flow rate 1 ml/min. Eluent A was 0.1%
trifluoroacetic acid (TFA) and eluent B was 0.1% TFA
with 90% acetonitrile (ACN) (both vol./vol.). The peak
of the peptide B21-B31 was collected with Fraction
Collector III (Waters, Milford, USA) and eluent was
evaporated as mentioned above.
Synthesis of Phenylthiohydantoin Amino Acid
Standards for Protein Sequencing
The water solutions of N-ε-acetyl-L-lysine (acK) and N-ε-N-ε-
N-ε-trimethyl-L-lysine (3meK, both from Sigma, St. Louis,
USA), containing 50 nmol each, were evaporated to dryness
in Eppendorf tubes and converted into phenylthiocarbamyl
(PTC) derivatives essentially as described elsewhere
(36). Obtained dry deposits were then converted into
phenylthiohydantoin (PTH) derivatives by dissolving
them in 100 μl portions of 25% (vol./vol.) TFA, 0.001%
(wt./vol.) dithiothreitol in water, flushing with argon, sealing,
and incubation for 30 min at 64°C. After this step the PTH
derivatives were purified by HPLC on a LC-18-DB
4.6×250 mm column (Supelco, Bellefonte, USA). Two sol-
vents were used: A – 0.1% TFA (all vol./vol.) and B – 0.07%
TFA, 80% ACN (vol./vol.). The linear gradient 0–100% of
the solvent B over 15 min, spectrophotometric detection at
269 nm, and 1 ml/min flow rate were applied. Fractions con-
taining PTH-acK and PTH-3meK were collected, evaporat-
ed to dryness, and kept at −20°C until use.
N-terminal Sequencing
Determination of N-terminal sequence of polypeptide chains
by Edman degradation was performed on a PPSQ30
(Shimadzu, Kyoto, Japan) automatic protein sequencer.
Before analyses the instrument was calibrated using a com-
mercial PTH proteinaceous amino acid standard mixture
(Wako, Osaka, Japan) and, separately, using the synthesized
PTH-acK as well as PTH-3meK. The calibration was per-
formed by 25 pmol amounts of these compounds, dissolved
previously in 37% (vol./vol.) ACN in water. The sequencing
was done using polypeptide chains absorbed on TFA-treated
glass fiber disks (Wako, Osaka, Japan) coated by polybrene
(Sigma, St. Louis, USA).
Mass Spectrometry
The insulin lispro derivative and endoproteinase Glu-C de-
rived peptides were analyzed in a reflector mode with the use
of 4800 Plus MALDI-TOF/TOF mass spectrometer (AB
SCIEX, Framingham, USA). α-cyano-4-hydroxy-cinnamic
acidmatrix was exploited. External calibration was performed
with a 4700 proteomics analyzer calibration mixture provided
by AB SCIEX. Data Explorer Software, Version 4.9, and
General Protein/Mass Analysis for Windows, version 8.2,
were applied for assignment of a, b and y ions to the MS/
MS spectrum of acetylated peptide. DeNovo Explorer (GPS
Explorer TM Software, Version 3.6) was exploited to match
the MS/MS spectrum to the annotated peptide sequence.
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RESULTS AND DISCUSSION
Insulin lispro is a short-acting insulin analogue produced
by recombinant DNA technology in E. coli as a precur-
sor which is further converted to the native hormone by
enzymes (Fig. 2).
During the production process, different impurities called
related proteins are formed at both biosynthesis and purifica-
tion steps. Related proteins constitute various modifications of
a desired protein including deamidated, methylated,
oxidized, cleaved, aggregated forms and adducts, just
to name a few, and they are present in a final bulk of a
drug substance. All can be monitored by various chromato-
graphic methods. Figure 3 illustrates the IEC-chromatogram
of insulin lispro manufactured at Institute of Biotechnology
and Antibiotics in Warsaw.
The main peak in this chromatogram is insulin lispro.
Small peaks arising from the baseline (seen in enlargement
in Fig. 3) are related proteins. The derivative peak 1 was
isolated and subjected for further investigation. Taking into
account the retention time relative to insulin lispro, derivative
1 was suspected to be one of intermediates possessing addi-
tional basic amino acids at chain B: Lys(B31) insulin lispro or
Lys(B31)Arg(B32) insulin lispro, which can appear during en-
zymatic conversion of the precursor (see Fig. 2). Surprisingly,
MALDI analysis of the collected fraction of peak 1 showed a +
42 mass increment when compared to the theoretical mass of
Lys(B31) insulin lispro (5932.7 Da) (Fig. 4). Such a change
Fig. 2 Scheme of enzymatic conversion of precursor during the production
process of insulin lispro.
Fig. 3 IEC chromatogram of insulin lispro.
Fig. 4 MALDI TOF spectrum of derivative 1.
Fig. 5 Peptide maps (RP-HPLC chromatograms) of insulin lispro and the
derivative 1 after enzymatic digestion with endoproteinase Glu-C; fragment
IV eluted at dead time.
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suggests trimethylation or acetylation of lysine. On the
basis of the recent discoveries of serine and threonine
acetylation by a bacterial effector from Yersinia (37), the-
se residues were also considered as suspicious during
our study. Moreover, two modifications, methylation
and formylation, can occur simultaneously within Lys(B31)
insulin lispro molecule resulting in +42 mass shift (14 Da+
28 Da).
Enzymatic digestion and peptide mapping were
employed to identify the modification site of the deriv-
ative. The experiment was performed in parallel with
insulin lispro. The complete digestion of insulin lispro
with endoproteinase Glu-C results in four fragments: I
(A5-A17, B1-B13) II (A18-A21, B14-B21), III (B22-B30),
IV (A1-A4). A small amount of intermediate fragment I
+ IV might be present due to slow hydrolysis of A4-A5
bond. When the peptide maps of insulin lispro and de-
rivative 1 were compared (see Fig. 5) the difference in
the retention time of the peak corresponding to frag-
ment III of the derivative and insulin lispro was ob-
served. It was indicative of a modification within fragment
III (peptide B22-B31).
Table I A Comparison Between the Calculated and Experimental Parent Ion Masses (Monoisotopic) of Peptide Fragments Resulted from Digestion of
Derivative 1 with Endoproteinase Glu-C
Fig. 6 MALDI TOF spectrum of derivative 1 after enzymatic digestion with
endoproteinase Glu-C. Fig. 7 MALDI-TOF/TOF spectrum of peptide B22-B31.
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Expected peptide fragments resulting from digestion of the
derivative with endoproteinase Glu-C are listed in Table I.
MALDI analysis of the digest gave a distinct signal at m/z
1286.7 (a sum of 1244.7+42; see Fig. 6) which was assigned
to peptide B22-B31 (fragment III of the derivative). As
this peptide does not contain any serine, further inves-
tigation was narrowed down to threonine and lysine
residues.
Tandemmass spectrometry was performed on this peptide
to explore the location and type of the modification. All b-type
ions seen inMS/MS spectrum (Fig. 7) were in agreement with
theoretical values, whereas y-type ions were 42 amu over the
predicted masses. The presence of two ions: b9 [1098.6] and
y1 [189.1] confirms that B30 Thr remains unmodified, while
B31 Lys is altered. The sequence of the peptide B22-B31 was
as follows: RGFFYTKPTKmod. Closer inspection of the
MS/MS spectrum revealed the presence of two diagnostic
ions for acetylated lysine at m/z 143.1 and m/z 126.1
(Fig. 8). Although the signal at m/z 143.1 can be also associ-
ated with mono-ethylated arginine, the co-presence of 143.1
with 126.1 undoubtedly indicates acetylation. The immonium
ion at m/z 126.1 is specific for lysine acetylation and enables
discrimination between acetylation and trimethylation of
lysine (38).
In order to confirm the type of modification in de-
rivative 1, Edman degradation was employed as an or-
thogonal method. During Edman degradation the auto-
matic protein sequencer consecutively detaches amino
acid residues from N-termini of the analyzed polypep-
tides, converts them into PTH derivatives and performs
their identification by HPLC chromatography. Since
standards of PTH derivatives of N-ε-acetyl-L-lysine
and N-ε-trimethyl-L-lysine are not commercially avail-
able, they were synthesized in the laboratory. Analysis
of the peptide B22-B31 gave the following 9-mer se-
quence: RGFFYTKPTKac (N-ε-acetyl-L-lysine was
ascertained at 10th position). The chromatograms illus-
trating the mentioned 10th amino acid residue of this
peptide superimposed on acK as well as 3meK standards
are presented in Fig. 9. Peaks belonging to the standards of
N-ε-acetyl-L-lysine and N-ε-trimethyl-L-lysine differ in reten-
tion time sufficiently to allow the exclusion of trimethylation at
B31 in the derivative.
On the basis of the presented results it is interesting that a
derivative with acetylated lysine at position B28 was dot de-
tected so far. It is possible that acetylation does not take place
in other locations than B31 or acetylated derivatives are
formed at undetectable levels. A new project is open now in
our institute to understandmechanism of acetylation in insulin
analogues produced in E. coli and to examine all possi-
ble acetylation sites. Details of this work will be published in
the future.
Fig. 8 Enlarged MALDI-TOF/TOF spectrum of peptide B22-B31 with diag-
nostic ions 126.1 and 143.1. Insert – structure of diagnostic ions.
Fig. 9 Identification of the 10th
residue of the peptide B22-B31
performed during Edman degrada-
tion. The illustration presents the
HPLC chromatogram of the PTH
amino acid residue detached during
10th cycle of sequencing,
superimposed on the chromato-
grams of the acK as well as 3meK
standards. The retention time of the
10th residue is identical as that of
N-ε-acetyl-L-lysine.
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CONCLUSIONS
Ion exchange chromatography analysis of related proteins in
development batches of recombinant insulin lispro revealed
the existence of unknown derivative in excess of the assumed
limit 0.1%. This derivative was monitored in all development
batches of insulin lispro and it occurred in a range of
<LOD – 0.8% depending on purification methods. The
molecular mass of the derivative was 42 Da higher that
the theoretical mass of Lys(B31) insulin lispro—one of the
expected process-related intermediates. Both, Edman se-
quencing and MS/MS fragmentation provided clear-cut evi-
dence of lysine acetylation and exclusion of trimethylation
contingency. The derivative was identified to be N-ε-acetyl-
L-lysine (B31) insulin lispro. We do not know at present if
acetylation of this insulin lispro derivative proceeds enzymat-
ically or with the participation of acetyl phosphate (AcP) as the
acetyl donor, but certainly our discovery is another indication
that lysine acetylation is a frequently occurring posttransla-
tional modification in E. coli. It is highly probable that our
finding does not close the above list of acetylated therapeutic
proteins produced in E. coli. A worldwide intensification of
research on protein acetylation should bring new discoveries
in this field.
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